Trade Mark Journal No.2026/004 23 January 2026
WO0000001895360 (1,5,42,44)
Office of origin: United States of America
Date of International Registration:4 December 2025
Date of designation in the UK:
4 December 2025
International priority date claimed: 1 July 2025
(United States of America)
(99262902)
- Class 1
- Chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes for the manufacture of probiotic pharmaceutical preparations, microbe-targeted pharmaceutical preparations, or host-targeted pharmaceutical preparations for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, and gastrointestinal and immunological diseases; chemicals, biochemicals, cells, and microbes for use in the manufacture of probiotic pharmaceutical preparations, microbe-targeted pharmaceutical preparations, or host-targeted pharmaceutical preparations, for in vitro and in vivo scientific or research use, and for use in industry and science.
- Class 5
- Probiotic pharmaceutical preparations and substances for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases; microbe-targeted pharmaceutical preparations and substances for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases; host-targeted pharmaceutical preparations and substances for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases; chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes being pharmaceutical preparations and substances for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, and gastrointestinal and immunological diseases.
- Class 42
- Providing medical research and scientific research information in the fields of pharmaceuticals, biochemistry, biotechnology, and clinical trials; drug discovery services; pharmaceutical research; research and development of new probiotic pharmaceutical products, microbe-targeted pharmaceutical products, or host-targeted pharmaceutical products; research in the fields of conducting clinical trials for others, biochemistry, and biotechnology.
- Class 44
- Providing medical information in the fields of diagnostic, prophylactic, and therapeutic properties of probiotic, microbe-targeted, or host-targeted pharmaceuticals.
Axial Therapeutics, Inc.
Representative: Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine CA 92614, UNITED STATES OF AMERICA